ABVC BioPharma amends licensing deal to allow $3.5M milestone paid incrementally

ABVC BIOPHARMA, INC.

On June 23, 2024, ABVC and BioLite amended licensing agreements with AiBtl BioPharma for CNS drugs MDD and ADHD.
The $3.5M second milestone payment can now be paid in increments (e.g., $50,000) at any time instead of lump sum.
Amendments apply to both the ABVC and BioLite license agreements; no other terms were changed.
Change suggests potential liquidity strain at licensee AiBtl BioPharma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.